Abstract 4792: Elucidating stem cell-specific metabolic pathways in normal and malignant hematopoiesis to target human acute myeloid leukemia stem cells
Authors: Stephanie Z. Xie, Elisa Laurenti, John E. Dick
Journal: Cancer Research (2014)

Abstract Metabolic alterations are a cancer hallmark but the metabolic requirements of hematopoietic stem cells (HSC) in general, and leukemic stem cells (LSCs) specifically are poorly understood, particularly beyond energy metabolism. By analyzing a comprehensive transcriptional roadmap of human hematopoiesis, and comparing this to a LSC signature developed from 84 primary human acute myeloid leukemia (AML) samples, we uncovered two unexpected findings: (1) several metabolic pathways, specifically in bioactive lipids, distinguish HSC from progenitors and are essential for their function; and LSC are more similar to HSC overall, but also possess specific metabolic pathways that are more comparable to those of normal progenitors. We compiled a comprehensive list of 67 genes involved in fatty acid metabolism based on literature and database information and found that 36 of these were differentially expressed between HSC and progenitors, with 24 of them higher in HSC. In particular, sphingolipid enzymes are differentially regulated throughout the hematopoietic hierarchy. Interesting, sphingosine-1-phosphate (S1P) plays a role in HSC egress and ceramide vs S1P levels serve as a rheostat to regulate growth and cell survival. We defined these 24 genes as a lipid stem signature, and find that it is enriched in the LSC gene expression profiles from our 84 primary AML cohort by GSEA analysis indicating that fatty acid metabolism is differentially regulated in LSCs and non-LSCs, as it is for HSCs vs. normal progenitors. Our signature was found to be prognostic for patient survival in a Dutch cohort of 181 cytogenetically normal AMLs. To determine if lipid metabolism plays a functional role in AML biology, we screened a fatty acid compound library using a novel AML cell line (8227) that retains hierarchical organization and assessed cell viability, phenotypic LSC content, and differentiation. We identified myriocin, which targets serine palmitoyltransferase (1st step of sphingolipid synthesis) in this screen. Myriocin decreased 8227 viability and altered differentiation in vitro and reduced leukemia burden in vivo following transplantation into NOD/SCID mice transgenic for human cytokines. Treatment of mice bearing primary AML xenografts, including those from therapy resistant and relapsed patients, with myriocin or its derivative FTY720, a S1P mimetic, resulted in reduction of leukemic engraftment. Moreover, serial transplantation of AML samples by limiting dilution showed decreased LSC frequency of FTY720- and myriocin-treated cells in secondary mice compared to vehicle-treated cells. Importantly, myriocin or FTY720 treatment do not disrupt engraftment in mice bearing normal hematopoietic grafts. Thus, sphingolipid biology in LSC is different from that of HSC, and we present a novel AML therapeutic strategy targeting bioactive sphingolipids as a means to eradicate LSC while sparing HSC. Citation Format: Stephanie Z. Xie, Elisa Laurenti, John E. Dick. Elucidating stem cell-specific metabolic pathways in normal and malignant hematopoiesis to target human acute myeloid leukemia stem cells. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 4792. doi:10.1158/1538-7445.AM2014-4792